Adverse effects of human immunoglobulin therapy
- PMID: 23835249
- DOI: 10.1016/j.tmrv.2013.05.004
Adverse effects of human immunoglobulin therapy
Abstract
Human immunoglobulin (IG) is used for IgG replacement therapy in primary and secondary immunodeficiency, for prevention and treatment of certain infections, and as an immunomodulatory agent for autoimmune and inflammatory disorders. IG has a wide spectrum of antibodies to microbial and human antigens. Several high-titered IGs are also available enriched in antibodies to specific viruses or bacterial toxins. IG can be given intravenously (IGIV), intramuscularly (IGIM) or by subcutaneous infusions (SCIG). Local adverse reactions such as persistent pain, bruising, swelling and erythema are rare with IGIV infusions but common (75%) with SCIG infusions. By contrast, adverse systemic reactions are rare with SCIG infusions but common with IGIV infusions, occurring as often as 20% to 50% of patients and 5% to 15% of all IGIV infusions. Systemic adverse reactions can be immediate (60% of reactions) occurring within 6 hours of an infusion, delayed (40% of reactions) occurring 6 hours-1 week after an infusion, and late (less than 1% of reactions), occurring weeks and months after an infusion. Immediate systemic reactions such as head and body aches, chills and fever are usually mild and readily treatable. Immediate anaphylactic and anaphylactoid reactions are uncommon. The most common delayed systemic reaction is persistent headache. Less common but more serious delayed reactions include aseptic meningitis, renal failure, thromboembolism, and hemolytic reactions. Late reactions are uncommon but often severe, and include lung disease, enteritis, dermatologic disorders and infectious diseases. The types, incidence, causes, prevention, and management of these reactions are discussed.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence.Autoimmun Rev. 2016 Jan;15(1):71-81. doi: 10.1016/j.autrev.2015.09.002. Epub 2015 Sep 16. Autoimmun Rev. 2016. PMID: 26384525 Review.
-
Adverse events associated with intravenous immunoglobulin therapy.Int Immunopharmacol. 2006 Apr;6(4):535-42. doi: 10.1016/j.intimp.2005.11.015. Epub 2005 Dec 13. Int Immunopharmacol. 2006. PMID: 16504916 Review.
-
Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.Ann Allergy Asthma Immunol. 2004 Jan;92(1):60-4. doi: 10.1016/S1081-1206(10)61711-5. Ann Allergy Asthma Immunol. 2004. PMID: 14756466 Clinical Trial.
-
Preparation and use of therapeutic antibodies primarily of human origin.Biologicals. 2008 Nov;36(6):363-74. doi: 10.1016/j.biologicals.2008.07.002. Epub 2008 Sep 11. Biologicals. 2008. PMID: 18789721 Review.
-
Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.Postgrad Med. 2011 Sep;123(5):186-93. doi: 10.3810/pgm.2011.09.2474. Postgrad Med. 2011. PMID: 21904101
Cited by
-
Clinical and economical impacts of guideline implementation by the pharmaceutical care unit for high cost medications in a referral teaching hospital.BMC Health Serv Res. 2018 Oct 24;18(1):815. doi: 10.1186/s12913-018-3627-3. BMC Health Serv Res. 2018. PMID: 30355286 Free PMC article.
-
Potential therapeutic approach of intravenous immunoglobulin against COVID-19.Allergy Asthma Clin Immunol. 2021 Oct 9;17(1):105. doi: 10.1186/s13223-021-00609-3. Allergy Asthma Clin Immunol. 2021. PMID: 34627384 Free PMC article. Review.
-
Amoxicillin-induced aseptic meningitis: clinical features, diagnosis and management.Eur J Med Res. 2023 Aug 27;28(1):301. doi: 10.1186/s40001-023-01251-y. Eur J Med Res. 2023. PMID: 37635233 Free PMC article.
-
Adverse effects of immunoglobulin G therapy: thromboembolism and haemolysis.Clin Exp Immunol. 2014 Dec;178 Suppl 1(Suppl 1):72-4. doi: 10.1111/cei.12518. Clin Exp Immunol. 2014. PMID: 25546769 Free PMC article. No abstract available.
-
Hand, Foot, and Mouth Disease: A Narrative Review.Recent Adv Inflamm Allergy Drug Discov. 2022;16(2):77-95. doi: 10.2174/1570180820666221024095837. Recent Adv Inflamm Allergy Drug Discov. 2022. PMID: 36284392 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources